Enliven Therapeutics, Inc.
ELVN
$27.25
-$0.54-1.94%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -16.48% | -14.07% | -20.99% | -19.14% | -24.36% |
| Total Depreciation and Amortization | -17.03% | -5.71% | 0.64% | 0.97% | 6.73% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 70.78% | 87.36% | 151.51% | 123.19% | 132.75% |
| Change in Net Operating Assets | 75.31% | -298.88% | 669.48% | -146.06% | -424.13% |
| Cash from Operations | 3.95% | -4.67% | 2.21% | -15.95% | -19.46% |
| Capital Expenditure | -259.09% | -172.41% | -248.08% | 68.12% | 70.47% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -383.68% | -9,275.00% | -244.14% | 89.98% | 75.75% |
| Cash from Investing | -382.93% | -9,554.28% | -244.14% | 89.96% | 75.75% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 64.71% | 177.20% | 2.42% | -82.88% | -45.33% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 64.36% | 176.81% | 183.08% | -50.49% | -43.16% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -205.42% | -96.05% | 178.05% | 66.76% | -2.56% |